Vapotherm Inc
F:VA21
Vapotherm Inc
EPS (Diluted)
Vapotherm Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Vapotherm Inc
F:VA21
|
EPS (Diluted)
-$9
|
CAGR 3-Years
17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
EPS (Diluted)
$5
|
CAGR 3-Years
0%
|
CAGR 5-Years
17%
|
CAGR 10-Years
6%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
EPS (Diluted)
$1
|
CAGR 3-Years
64%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
EPS (Diluted)
$8
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
EPS (Diluted)
$3
|
CAGR 3-Years
-2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
2%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
EPS (Diluted)
$7
|
CAGR 3-Years
29%
|
CAGR 5-Years
22%
|
CAGR 10-Years
16%
|
|
Vapotherm Inc
Glance View
Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. The company is headquartered in Exeter, New Hampshire and currently employs 510 full-time employees. The company went IPO on 2018-11-14. The firm is focused on the care of patients of all ages suffering from the respiratory distress often associated with complex lung diseases, such as chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), pneumonia, asthma and COVID-19. Its device solutions are focused on high velocity nasal insufflation (HVNI), which delivers non-invasive ventilatory support to patients suffering from respiratory distress. Its HVNI technology delivers heated, humidified and oxygenated air at a high velocity through a small-bore nasal interface. The company offers four versions of its Precision Flow systems, which includes Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. Its Precision Flow systems include a capital unit, a single-use disposable and a nasal interface. Its digital solutions are focused on at home patient monitoring. The firm also provides various clinical solutions.
See Also
What is Vapotherm Inc's EPS (Diluted)?
EPS (Diluted)
-9.6
USD
Based on the financial report for Dec 31, 2023, Vapotherm Inc's EPS (Diluted) amounts to -9.6 USD.
What is Vapotherm Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
14%
Over the last year, the EPS (Diluted) growth was 72%. The average annual EPS (Diluted) growth rates for Vapotherm Inc have been 17% over the past three years , 14% over the past five years .